BamSEC and AlphaSense Join Forces
Learn More

Mabvax Therapeutics Holdings, Inc.

Formerly OTC: MBVXQ
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q/A 55 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed; and Is Indicated With Brackets Where the Information Has Been Omitted From the Filed Version of This Exhibit. Asset Purchase and License Agreement by and Between Boehringer Ingelheim International Gmbh and Mabvax Therapeutics Holdings, Inc. and Mabvax Therapeutics, Inc. Bii Contract No: [***] -1
12/34/56
EX-10.1
from 10-Q/A 55 pages Asset Purchase and License Agreement
12/34/56
EX-10.3
from 8-K 1 page Mabvax Therapeutics Holdings, Inc.,
12/34/56
EX-10.2
from 8-K 12 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 39 pages Equity Purchase Agreement
12/34/56
EX-10.1
from 10-Q 52 pages Asset Purchase and License Agreement by and Between Boehringer Ingelheim International Gmbh and Mabvax Therapeutics Holdings, Inc. and Mabvax Therapeutics, Inc. Bii Contract No: [***] Portions of This Exhibit, Indicated by the Mark “[***],” Were Omitted and Have Been Filed Separately With the Secretary of the Commission Pursuant to the Registrant’s Application Requesting Confidential Treatment Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as Amended
12/34/56
EX-10.6
from 10-Q 16 pages Sublicense Agreement
12/34/56
EX-10.3
from 8-K 2 pages Re: Letter Agreement Mabvax Therapeutics Holdings, Inc. (The “Company”) and the Undersigned Hereby Agree Pursuant to This Agreement (This “April 2018 Letter Agreement”) That: A. April 2018 Inducement Shares
12/34/56
EX-10.2
from 8-K 15 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 28 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 28 pages Securities Purchase Agreement
12/34/56
EX-10.40
from S-1 3 pages Subscription Agreement
12/34/56
EX-10.2
from 8-K 13 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 12 pages Exchange Agreement
12/34/56
EX-10.1
from 8-K 5 pages Subscription Agreement
12/34/56
EX-10.1
from 8-K 5 pages Subscription Agreement
12/34/56
EX-10.1
from 8-K 6 pages Subscription Agreement
12/34/56
EX-10.1
from 8-K 26 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Mabvax Therapeutics Holdings, Inc. (The “Company”) and Hs Contrarian Investments, LLC (“Hsci”) Hereby Agree Pursuant to This Agreement (This “Letter Agreement”) That: A. $2,350,000 Financing
12/34/56